<DOC>
	<DOCNO>NCT00491634</DOCNO>
	<brief_summary>The study hypotheses introduction dose escalate treosulfan , substitution busulfan , reduce toxicity allogeneic transplantation improve myeloablation disease control patient AML MDS eligible standard transplantation .</brief_summary>
	<brief_title>Treosulfan-based Conditioning Transplantation AML/MDS</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Treosulfan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>1 . Age less physiologic 68 year . 2 . Patients AML MDS eligible standard TBI Busulfanbased myeloablative conditioning due age , concurrent medical condition , extensive prior therapy ( e.g . age &gt; 55 year HLAmatched sibling transplant &gt; 50 match unrelated donor transplant , prior / concomitant pulmonary , liver , organ complication ) . 3 . This study include patient chemorefractory disease previously untreated active disease . A. acute myeloid leukemia ( AML ) accord WHO classification ( &gt; 20 % myeloblast peripheral blood bone marrow diagnosis ) induction failure , PR , untreated chemorefractory relapse . Patients must &gt; 10 % marrow blast time transplantation . B. myelodysplastic syndrome ( MDS ) accord WHO classification ( &lt; 20 % myeloblast peripheral blood bone marrow diagnosis ) , indicate allogeneic transplantation : refractory anaemia excess blast ( RAEB1 RAEB2 ) prior therapy 4 . Patients must HLA match related unrelated donor willing donate either peripheral blood stem cell bone marrow . Matching base highresolution class I ( HLAA , B , C ) class II ( HLADRB1 , DQB1 ) typing . The goal transplant &gt; 3 x 106 CD34+ cell per kg body weight recipient 1 . Bilirubin &gt; 3.0 mg/dl , transaminases &gt; 3 time upper normal limit 2 . Creatinine &gt; 2.0 mg/dl 3 . ECOGPerformance status &gt; 2 4 . Uncontrolled infection 5 . Pregnancy lactation 6 . Abnormal lung diffusion capacity ( DLCO &lt; 40 % predict ) 7 . Severe cardiovascular disease 8 . CNS disease involvement 9 . Pleural effusion ascites &gt; 1 liter 10 . Known hypersensitivity fludarabine treosulfan 11 . Psychiatric conditions/disease impair ability give inform consent adequately cooperate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>allogeneic stem cell transplantation</keyword>
	<keyword>reduced-intensity conditioning</keyword>
	<keyword>treosulfan</keyword>
</DOC>